Welcome!

News Feed Item

Phase 2 Results Show INCIVO® (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic Hepatitis C Virus and HIV

BOSTON, Massachusetts, November 10, 2012 /PRNewswire/ --

-  Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO® (telaprevir)-based regimen -

Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today presented results from a new phase 2 study which shows that an INCIVO® (telaprevir)-based regimen was effective in achieving a sustained virological response at 24 weeks (SVR24) in patients co-infected with both genotype-1 chronic hepatitis C virus (HCV) and HIV (HCV/HIV) compared to patients receiving a placebo with the standard HCV treatment, peginterferon alfa and ribavirin (74 vs. 45 percent).[1]

An estimated 130 to 210 million people are infected with HCV worldwide[2], with HCV/HIV co-infections averaging about 40 percent of HCV patients in Europe.[3]  People co-infected with HCV/HIV have more rapid fibrosis progression and liver disease than patients with HCV alone.[3] Chronic HCV infections can lead to end-stage liver disease, which is a major cause of death in HCV/HIV co-infected patients.[3] Despite the added health consequences of co-infection, only a small proportion of HCV/HIV co-infected patients receive treatment for their hepatitis.[3]

"The new data further demonstrate the potential efficacy and safety of telaprevir when used in combination with peginterferon alfa and ribavirin in HCV/HIV co-infected patients. New effective treatment regimens are particularly important for this patient group due to their high risk of rapidly developing liver complications," said investigator, Kenneth E. Sherman, M.D., of the University of Cincinnati College of Medicine.

The phase 2 study was a two-part randomized, double-blind, placebo-controlled, parallel-group, trial of telaprevir with a standard HCV treatment combination of peginterferon alfa and ribavirin (PR) in previously untreated patients with genotype-1 chronic HCV/HIV co-infection. The study treated a total of 60 HCV/HIV co-infected patients who did or did not receive a concomitant stable antiretroviral therapy (ART) regimen.[1] During the study, no patients receiving a telaprevir-based regimen experienced HIV RNA breakthroughs and their CD4 T-cell count percentage remained unchanged.[1]

The safety and tolerability of a telaprevir-based regimen for treating HCV in HCV/HIV co-infected patients were comparable to that previously observed in HCV mono-infected patients.[1] Adverse events that occurred more frequently (>10 percent difference) in HCV/HIV co-infected patients receiving telaprevir and PR compared to HCV/HIV co-infected patients taking PR alone included pruritus (itchiness), headache, nausea, rash and dizziness.[1]

"Now that ART for people living with HIV has improved so vastly over the years in controlling their HIV, it has become increasingly important to address the consequences of chronic HCV infection in patients co-infected with HCV/HIV. Janssen remains committed to addressing the unmet needs of patients and increasing the availability of new treatment options for patient groups who have been largely underserved until now", said Alessandra Baldini, Medical Affairs Director, Janssen.

The analysis of the data from this study, AASLD Abstract Final ID: 54, will be submitted for peer-review publication.

Additional telaprevir data being presented at AASLD (http://www.aasld.org/lm2012)includes:

  • Non-inferior SVR rates in previously untreated genotype-1 HCV patients receiving a telaprevir-based regimen twice-daily versus every eight hours.[4]    Abstract (Final ID: LB-8)
  • Telaprevir Global Early Access Programme efficacy and safety data regarding treatment among genotype-1 HCV patients with severe fibrosis or compensated cirrhosis.[5]Abstract (Final ID: LB-15)
  • Factors predictive of anemia development in treatment-experienced patients receiving telaprevir plus PR in the REALIZE trial.[6] Abstract (Final ID: 771)
  • Rate of disappearance of telaprevir-resistant variants using clonal and population sequence data from Phase 3 studies.[7] Abstract (Final ID: 756)
  • Evaluation of liver and plasma HCV RNA kinetics and telaprevir levels in genotype-1 HCV patients treated with telaprevir using serial fine needle aspirates.[8]Abstract (Final ID: 215)
  • Deep sequencing of the HCV NS3/4A region confirms low prevalence of telaprevir-resistant variants.[9] Abstract (Final ID: 1091)

About INCIVO®

INCIVO® (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic HCV in adult patients with compensated liver disease (including cirrhosis) who are treatment naïve, and who have previously been treated with interferon alfa (pegylated or non pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.[10]  INCIVO® is a small molecule, selective inhibitor of the HCV serine protease, and a member of the new class of medicine for the treatment of genotype-1 chronic HCV, direct acting antivirals (DAAs).  Unlike previous treatments, DAAs act directly on viral enzymes and prevent the virus from replicating.  INCIVO® was approved by the European Commission on 19 September 2011.  


Telaprevir was developed by Janssen Infectious Diseases - Diagnostics BVBA, one of the Janssen Pharmaceutical Companies, in collaboration with Vertex Pharmaceuticals (Vertex) and Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe Pharma). Janssen has rights to commercialize telaprevir in Europe, South America, Australia, the Middle East and certain other countries. Vertex has rights to commercialize telaprevir in North America where it is being marketed under the brand name INCIVEK[TM].  Mitsubishi Tanabe Pharma has rights to commercialize telaprevir in Japan and certain Far East countries where it is being marketed as TELAVIC®.

Important Safety Information

Please see full Summary of Product Characteristics or visit http://www.emea.europa.eu for more details.

The overall safety profile of telaprevir is based on the Phase 2/3 clinical development programme containing 2,641 patients who received a telaprevir-based regimen. In clinical trials, the incidence of adverse events of at least moderate intensity was higher in the telaprevir group than in the placebo group (both groups receiving peginterferon alfa and ribavirin). The most frequently reported adverse reactions (incidence ≥ 5.0%) of at least grade 2 in severity were anemia, rash, pruritus, nausea, and diarrhoea during the telaprevir treatment phase, and the most frequently reported adverse reactions (incidence ≥ 1.0%) of at least Grade 3 were anemia, rash, thrombocytopenia, lymphopenia, pruritus, and nausea.[10]

Rash events were reported in 55% of patients with a telaprevir-based regimen compared to 33% of patients treated with peginterferon alfa and ribavirin only and more than 90% of rashes were of mild or moderate severity. Severe rashes were reported with telaprevir combination treatment in 4.8% of patients. Rash led to discontinuation of telaprevir alone in 5.8% of patients and 2.6% of patients discontinued telaprevir combination treatment for rash events compared to none of those receiving peginterferon alfa and ribavirin.[10]

Hemoglobin values of < 10 g/dl were observed in 34% of patients who received telaprevir combination treatment and in 14% of patients who received peginterferon alfa and ribavirin. In placebo-controlled Phase 2 and 3 trials, 1.9% of patients discontinued telaprevir alone due to anemia, and 0.9% of patients discontinued INCIVO® combination treatment due to anemia compared to 0.5% receiving peginterferon alfa and ribavirin.[10]

About HCV

HCV is a blood-borne infectious disease that affects the liver.[11,12] With an estimated 130-210 million people infected worldwide,[2] and three to four million people newly infected each year, HCV puts a significant burden on patients and society.[13] Estimations indicate that HCV caused more than 86,000 deaths and 1.2 million disability-adjusted life-years (DALYs) in the WHO European region in 2002 (latest data available).[14] Chronic infection with HCV can lead to liver cancer and other serious and fatal liver diseases.[15] About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV (latest data available).[14]  The previously accepted standard  treatment for HCV was peginterferon alfa combined with ribavirin,[16] however this only cleared the virus for 40-50 percent of genotype-HCV patients.[16,17]

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Infectious Diseases - Diagnostics BVBA is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

References:

  1. Sulkowski MS, Sherman KE, Soriano V, et al. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: 54).
  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2011; 55: 245-264.
  3. WHO EUROPE. Management of Hepatitis C and HIV co-infection - Clinical protocol for the WHO European Region. Available at: http://www.euro.who.int/data/assets/pdf_file/0008/78146/E90840_Chapter_6.pdf. Last accessed September 12, 2012.
  4. Buti M, Agarwal K, Horsmans Y, et al. OPTIMIZE Trial: Non-inferiority of twice-daily telaprevir versus administration of every 8 hours in treatment-naïve, genotype 1 HCV infected patients. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: LB-8)
  5. Colombo M et al. Treatment of Hepatitis C Genotype 1 Patients with Severe Fibrosis or Compensated Cirrhosis: The International Telaprevir Early Access Program. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: LB-15)
  6. Zeuzem S, DeMasi R, Baldini A, et al. Factors predictive of anemia development in treatment-experienced patients receiving telaprevir (T;TVR) plus peginterferon/ribavirin (PR) in the REALIZE trial. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: 771).
  7. Sullivan J, De Meyer S, Haseltine E, et al. Rate of disappearance of telaprevir resistant variants using clonal and population sequence data from Phase 3 studies. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: 756).
  8. Talal A, Dimova R, Zhang E, et al. Evaluation of Liver And Plasma HCV RNA Kinetics And Telaprevir Levels In Genotype 1 HCV Patients Treated With Telaprevir (TVR) Using Serial Fine Needle Aspirates (FNA). 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: 215).
  9. Dierynck I, De Meyer S, Thys K, et al. Deep Sequencing of the HCV NS3/4A Region Confirms Low Prevalence of Telaprevir-resistant Variants Both at Baseline and End of Study. 2012. American Association for the Study of Liver Diseases (AASLD) Abstract (Final ID: 1091).
  10. Incivo® Summary of Product Characteristics, updated 2011
  11. Simin, M et al. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2007; 25(10):1153-62.
  12. Centres for Disease Control and Prevention. Hepatitis C FAQs. [cited 2009 Dec 17] Available from: http://www.cdc.gov/hepatitis/C/cFAQ.htm#transmission
  13. WHO. State of the art of vaccine research and development. Viral Cancers. Available from http://www.who.int/vaccine_research/documents/Viral_Cancers.pdf
  14. Mühlberger, N et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009; 9(34):1-14.
  15. Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. Expert Review of Vaccines 2008;7(7): 915-923.
  16. McHutchison, J et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med. 2009; 361:580-93.
  17. The Hepatitis C Trust. Treatments: Potential New Drugs. [cited 2010 Feb 20] Available from:  http://www.hepctrust.org.uk/treatment/potential-new-drugs/Drugs+that+target+the+virus


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Internet of @ThingsExpo has announced today that Chris Matthieu has been named tech chair of Internet of @ThingsExpo 2017 New York The 7th Internet of @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, New York. Chris Matthieu is the co-founder and CTO of Octoblu, a revolutionary real-time IoT platform recently acquired by Citrix. Octoblu connects things, systems, people and clouds to a global mesh network allowing users to automate and control design flo...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.